Payment overview · 2025
General Payments
$663.85
22 reported records · 10 companies
Healthcare provider profile · identity verified
Natalie Rodriguez, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BENTON, AR · NPI 1033886809
Verified facts
What the public records show
CMS Open Payments records show Natalie Rodriguez, APRN received $663.85 in general payments during 2025 across 22 reported records.
Supernus Pharmaceuticals, Inc. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $203.21 | 30.6% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.17 | 20.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.50 | 15.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.72 | 8.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.51 | 7.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.47 | 6.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.25 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.66 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.28 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.08 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $663.85 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $203.21 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $137.17 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $104.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.72 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 63 |
| Lisinopril | Lisinopril | 262 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 238 | 63 |
| Gabapentin | Gabapentin | 231 | 49 |
| Omeprazole | Omeprazole | 193 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 29 |
| Losartan Potassium | Losartan Potassium | 137 | 27 |
| Metformin Hcl | Metformin Hcl | 132 | 26 |
| Furosemide | Furosemide | 126 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 17 |
| Meloxicam | Meloxicam | 97 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 92 | 18 |
| Trazodone Hcl | Trazodone Hcl | 88 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 21 |
| Montelukast Sodium | Montelukast Sodium | 74 | 14 |
| Potassium Chloride | Potassium Chloride | 71 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 12 |
| Ozempic | Semaglutide | 64 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 19 |
| Simvastatin | Simvastatin | 57 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 56 | 16 |
| Eliquis | Apixaban | 54 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 30 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 19 |
| Glipizide | Glipizide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $663.85 · 22 records | Supernus Pharmaceuticals, Inc. | AIRSUPRA, BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, NURTEC ODT, QULIPTA, Qelbree, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error